We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.
- Authors
Alonso-Navarro, Rodrigo; Ramírez, Margarita; Masiá, Mar; Paredes, Roger; Montejano, Rocío; Povar-Echeverria, Marina; Carratalà, Jordi; Salavert, Miguel; Bernal, Enrique; Dueñas, Carlos; Flores, Juan; Fanjul, Francisco; Gutiérrez, Isabel; Rico, Verónica; Mateu, Lourdes; Cadiñanos, Julen; Berenguer, Juan; Soriano, Alex
- Abstract
Background: Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods: We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 h of the first dose of remdesivir. Results: In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p = 0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤ 5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31–0.92; p = 0.024). Conclusion: For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission.
- Subjects
REMDESIVIR; COVID-19; ANTI-inflammatory agents; SYMPTOMS; HOSPITAL patients
- Publication
BMC Infectious Diseases, 2023, Vol 23, Issue 1, p1
- ISSN
1471-2334
- Publication type
Article
- DOI
10.1186/s12879-023-08222-y